Amgen Raises Forecast on $10.4B Q3 Revenue

Amgen on November 3, 2026 reported third-quarter revenue of about $10.4 billion, up roughly 8% from $9.557 billion a year earlier, and raised full-year 2026 guidance for the third time. GAAP EPS rose to $7.08 from $5.93 and non-GAAP EPS to $6.45 from $5.64, beating consensus of $10.06 billion revenue and $5.78 adjusted EPS. Product sales hit $9.883 billion. Repatha rose 37% to $1.085 billion, EVENITY 39% to $751 million and TEZSPIRE 43% to $538 million; UPLIZNA jumped 191% to $451 million. Prolia fell 45% and XGEVA 47% on biosimilar competition. Free cash flow was $3.7 billion, down from $4.2 billion on working-capital timing. Chairman and CEO Robert Bradway said Amgen "delivered another strong quarter as our strategy for long-term growth continued to produce results across the enterprise" and that commercial strength, clinical advances and a late-stage pipeline reinforce confidence in "durable growth well into the next decade." Full-year guidance is revenue of $38.9 billion to $39.7 billion and adjusted EPS of $22.90 to $23.70. RTTNews listed revenue at $10.365 billion, up 8.5%; other outlets cited about $10.4 billion, up 8%.